Close Menu

NEW YORK – Clinical-stage oncology company AnHeart Therapeutics said on Monday that the Chinese drug evaluation agency has granted investigational new drug authorization to its lead candidate taletrectinib, allowing it to start two Phase II trials in the next few months.

Taletrectinib is a ROS1 and NTRK inhibitor that AnHeart licensed from Daiichi Sankyo. The drug inhibits both ROS1 wild-type and major crizotinib-resistant mutations, including G2032R. There are currently no approved drugs that are effective against resistant mutations like G2032R.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.